A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALKfusion gene

Tanaka, Hisashi; Hayashi, Akihito; Morimoto, Takeshi; Taima, Kageaki; Tanaka, Yoshihito; Shimada, Michiko; Kurose, Akira; Takanashi, Shingo; Okumura, Ken

doi:10.1186/1471-2407-12-558

Cited by 40 publications

(23 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Seven had an objective response to EGFR TKIs, while three did not [5,9,[21][22][23][24][25]. In other four cases no information are reported [5,10] (Table 1).…”

Section: Treatmentmentioning

confidence: 84%

Coexistence of EGFR mutation and ALK translocation in NSCLC: Literature review and case report of response to gefitinib

Santelmo¹,

Ravaioli²,

Barzotti³

et al. 2013

Lung Cancer

View full text Add to dashboard Cite

“…Seven had an objective response to EGFR TKIs, while three did not [5,9,[21][22][23][24][25]. In other four cases no information are reported [5,10] (Table 1).…”

Section: Treatmentmentioning

confidence: 84%

Coexistence of EGFR mutation and ALK translocation in NSCLC: Literature review and case report of response to gefitinib

Santelmo¹,

Ravaioli²,

Barzotti³

et al. 2013

Lung Cancer

View full text Add to dashboard Cite

“…However, discordant results have been reported by studies investigating tumours with these concomitant molecular alterations, resulting in resistance and response to the same drug being reported by different studies (13–17). …”

Section: Discussionmentioning

confidence: 79%

Response to erlotinib in a patient with lung adenocarcinoma harbouring the EML4-ALK translocation: A case report

et al. 2015

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer-associated mortality worldwide, and the mainstay of treatment remains to be personalised therapy. Tyrosine kinase inhibitors of the epidermal growth factor receptor (EGFR-TKIs) have been reported to exert a significant impact in the treatment of non-small cell lung cancer (NSCLC), particularly in patients harbouring mutations in the EGFR gene. The echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) gene translocation has been described in a subset of patients with NSCLC and possesses potent oncogenic activity. This translocation represents one of the most novel molecular targets in the treatment of NSCLC. Patients who harbour the EML4-ALK rearrangement possess lung tumours that lack EGFR or K-ras mutations. The present study reports the case of a patient possessing the EML4-ALK rearrangement that was initially treated with erlotinib and achieved a lasting clinical response. To the best of our knowledge, the current study is the first report of a clinical response to EGFR-TKI in a patient with lung adenocarcinoma harbouring the EML4-ALK fusion gene, but no EGFR mutations. However, as the disease progressed, the ALK gene status of the tumour was investigated, and based upon a positive result, the patient was treated with crizotinib and achieved a complete response. In conclusion, the present study suggests that the EML4-ALK rearrangement is not always associated with resistance to EGFR-TKIs. Further studies are required to clarify the biological features of these tumours and to investigate the mechanisms underlying the primary resistance to EGFR-TKIs when the EML4-ALK rearrangement is present.

show abstract

“…Several case reports indicated that the presence of concomitant EGFR mutations and ALK rearrangements might be associated with mutual resistance to single-agent crizotinib or EGFR-TKIs (Shaw et al, 2009;Sasaki et al, 2011;Tiseo et al, 2011;Tanaka et al, 2012). Other studies reported good response to EGFR-TKIs (Wang et al, 2012;Santelmo et al, 2013;Yang et al, 2014) or crizotinib Yang et al, 2014).…”

Section: Discussionmentioning

confidence: 99%

Clinical characteristics of patients with non-small cell lung cancers harboring anaplastic lymphoma kinase rearrangements and primary lung adenocarcinoma harboring epidermal growth factor receptor mutations

Lei

Wang

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Echinoderm microtubule associated protein like 4-anaplastic lymphoma kinase (EML4-ALK) gene rearrangements and epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) have been intensively studied. The objective of this study was to determine the clinicopathological characteristics in genotype-specific subsets of patients with NSCLC to help ensure the optimal identification of patients whose tumors harbor these two driver mutations. The incidence of ALK rearrangements was investigated in 763 NSCLC specimens by immunohistochemistry using a D5F3 antibody, and EGFR mutations were assessed by amplification refractory mutation system (ARMS) in 222 patients with lung adenocarcinoma. Of these, 73 (9.6%) were detected as being ALK-positive; this designation was associated with young age, female gender, never-smokers, lymph node metastasis, and poor tumor differentiation, but not with histology. EGFR mutations were identified in 102 (45.9%) of 222 adenocarcinoma samples, and were more frequent in females and never-smokers. No difference in age was observed. Specifically, we identified several cases of complex EGFR mutations, and concomitant EGFR mutations and ALK rearrangements. These results suggest that young women and never-smokers are at risk for ALK rearrangement. We also identified concomitant mutations of EGFR and rearrangements of ALK in this study.

show abstract

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALKfusion gene

Cited by 40 publications

References 11 publications

Coexistence of EGFR mutation and ALK translocation in NSCLC: Literature review and case report of response to gefitinib

Coexistence of EGFR mutation and ALK translocation in NSCLC: Literature review and case report of response to gefitinib

Response to erlotinib in a patient with lung adenocarcinoma harbouring the EML4-ALK translocation: A case report

Clinical characteristics of patients with non-small cell lung cancers harboring anaplastic lymphoma kinase rearrangements and primary lung adenocarcinoma harboring epidermal growth factor receptor mutations

Contact Info

Product

Resources

About